Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoioetic stem cell transplantation

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The hematopoietic stem cell transplantation (HSCT) setting is a rapidly evolving field, and procedures with a high degree of complexity are now entering into the clinic. The risk of developing opportunistic viral infections increases with the level of human leukocyte antigen disparity between the donor and the recipient of allogeneic HSCT and is enhanced by graft manipulations such as T-cell depletion or immune suppression required to control graft versus host disease (GVHD) or rejection. Among the opportunistic viral infections potentially hampering the outcome of HSCT, human cytomegalovirus (HCMV) infection plays a major role. In the early 1980s, before the introduction of effective antiviral treatment, HCMV disease accounted for the high mortality in recipients of allogeneic HSCT. In more recent years, the availability of HCMV-specific antiviral agents (ganciclovir, GCV, foscarnet, PFA and cidofovir, CDV) led to a dramatic decrease in HCMV-related morbidity and mortality. However, HCMV infection still remains a major concern in the HSCT setting. Historically, treatment of HCMV infection in HSCT recipients (HSCTR) evolved from treatment of overt HCMV disease to universal prophylaxis or pre-emptive treatment of active infection, in parallel with the improvement of techniques for diagnosing and monitoring HCMV infection in transplant recipients.

Original languageEnglish
Pages (from-to)123-130
Number of pages8
JournalHematological Oncology
Volume26
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Stem Cell Transplantation
Cytomegalovirus
Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Opportunistic Infections
Virus Diseases
Therapeutics
Antiviral Agents
Foscarnet
Ganciclovir
Mortality
Graft vs Host Disease
HLA Antigens
Tissue Donors
Morbidity
T-Lymphocytes
Transplants
Infection

Keywords

  • Hematopoietic stem cell transplantation
  • Human cytomegalovirus
  • Pre-emptive treatment
  • Viral load measurement

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{2436254e191e48909fa0bf25b7c6c339,
title = "Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoioetic stem cell transplantation",
abstract = "The hematopoietic stem cell transplantation (HSCT) setting is a rapidly evolving field, and procedures with a high degree of complexity are now entering into the clinic. The risk of developing opportunistic viral infections increases with the level of human leukocyte antigen disparity between the donor and the recipient of allogeneic HSCT and is enhanced by graft manipulations such as T-cell depletion or immune suppression required to control graft versus host disease (GVHD) or rejection. Among the opportunistic viral infections potentially hampering the outcome of HSCT, human cytomegalovirus (HCMV) infection plays a major role. In the early 1980s, before the introduction of effective antiviral treatment, HCMV disease accounted for the high mortality in recipients of allogeneic HSCT. In more recent years, the availability of HCMV-specific antiviral agents (ganciclovir, GCV, foscarnet, PFA and cidofovir, CDV) led to a dramatic decrease in HCMV-related morbidity and mortality. However, HCMV infection still remains a major concern in the HSCT setting. Historically, treatment of HCMV infection in HSCT recipients (HSCTR) evolved from treatment of overt HCMV disease to universal prophylaxis or pre-emptive treatment of active infection, in parallel with the improvement of techniques for diagnosing and monitoring HCMV infection in transplant recipients.",
keywords = "Hematopoietic stem cell transplantation, Human cytomegalovirus, Pre-emptive treatment, Viral load measurement",
author = "Fausto Baldanti and Daniele Lilleri and Giuseppe Gema",
year = "2008",
doi = "10.1002/hon.856",
language = "English",
volume = "26",
pages = "123--130",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoioetic stem cell transplantation

AU - Baldanti, Fausto

AU - Lilleri, Daniele

AU - Gema, Giuseppe

PY - 2008

Y1 - 2008

N2 - The hematopoietic stem cell transplantation (HSCT) setting is a rapidly evolving field, and procedures with a high degree of complexity are now entering into the clinic. The risk of developing opportunistic viral infections increases with the level of human leukocyte antigen disparity between the donor and the recipient of allogeneic HSCT and is enhanced by graft manipulations such as T-cell depletion or immune suppression required to control graft versus host disease (GVHD) or rejection. Among the opportunistic viral infections potentially hampering the outcome of HSCT, human cytomegalovirus (HCMV) infection plays a major role. In the early 1980s, before the introduction of effective antiviral treatment, HCMV disease accounted for the high mortality in recipients of allogeneic HSCT. In more recent years, the availability of HCMV-specific antiviral agents (ganciclovir, GCV, foscarnet, PFA and cidofovir, CDV) led to a dramatic decrease in HCMV-related morbidity and mortality. However, HCMV infection still remains a major concern in the HSCT setting. Historically, treatment of HCMV infection in HSCT recipients (HSCTR) evolved from treatment of overt HCMV disease to universal prophylaxis or pre-emptive treatment of active infection, in parallel with the improvement of techniques for diagnosing and monitoring HCMV infection in transplant recipients.

AB - The hematopoietic stem cell transplantation (HSCT) setting is a rapidly evolving field, and procedures with a high degree of complexity are now entering into the clinic. The risk of developing opportunistic viral infections increases with the level of human leukocyte antigen disparity between the donor and the recipient of allogeneic HSCT and is enhanced by graft manipulations such as T-cell depletion or immune suppression required to control graft versus host disease (GVHD) or rejection. Among the opportunistic viral infections potentially hampering the outcome of HSCT, human cytomegalovirus (HCMV) infection plays a major role. In the early 1980s, before the introduction of effective antiviral treatment, HCMV disease accounted for the high mortality in recipients of allogeneic HSCT. In more recent years, the availability of HCMV-specific antiviral agents (ganciclovir, GCV, foscarnet, PFA and cidofovir, CDV) led to a dramatic decrease in HCMV-related morbidity and mortality. However, HCMV infection still remains a major concern in the HSCT setting. Historically, treatment of HCMV infection in HSCT recipients (HSCTR) evolved from treatment of overt HCMV disease to universal prophylaxis or pre-emptive treatment of active infection, in parallel with the improvement of techniques for diagnosing and monitoring HCMV infection in transplant recipients.

KW - Hematopoietic stem cell transplantation

KW - Human cytomegalovirus

KW - Pre-emptive treatment

KW - Viral load measurement

UR - http://www.scopus.com/inward/record.url?scp=54849417659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849417659&partnerID=8YFLogxK

U2 - 10.1002/hon.856

DO - 10.1002/hon.856

M3 - Article

VL - 26

SP - 123

EP - 130

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -